Retinopathy of Prematurity 

  • Author: KN Siva Subramanian, MD; Chief Editor: Ted Rosenkrantz, MD   more...
 
Updated: May 18, 2011
 

Background

Retinopathy of prematurity (ROP) is a serious vasoproliferative disorder that affects extremely premature infants. Retinopathy of prematurity often regresses or heals but can lead to severe visual impairment or blindness. Significant retinopathy of prematurity can lead to lifelong disabilities for the smallest survivors of neonatal ICUs (NICUs). It remains a serious problem despite striking advances in neonatology.

Next

Pathophysiology

Retinopathy of prematurity primarily occurs in extremely low birth weight (ELBW) infants. Most research suggests that a low birth weight, a young gestational age (GA), and the severity of illness (eg, respiratory distress syndrome [RDS], bronchopulmonary dysplasia [BPD], sepsis) are associated factors. Recently, other associations have been described. However, the severity of the illness appears to be a major predictor of severe disease. The smallest, sickest, and most immature infants are at the highest risk for serious disease. Black infants appear to have less severe retinopathy of prematurity.

Retinal vasculature begins to develop around 16 weeks' gestation. It grows circumferentially and becomes fully mature at term. Premature birth results in the cessation of normal retinal vascular maturation. Exposure of newborn premature infants to hyperoxia downregulates retinal vascular endothelial growth factor (VEGF). Blood vessels constrict and can become obliterated, resulting in delays of normal retinal vascular development. This hyperoxia-vasocessation is known as stage I of retinopathy of prematurity. See the image below.

Stage I retinopathy of prematurity. Stage I retinopathy of prematurity.

Early on, oxygen and nutrients can be delivered to the retina by means of diffusion from the underlying choroid capillary bed. The retina continues to grow in thickness and eventually outgrows its vascular supply. Over time, retinal hypoxia occurs and results in an overgrowth of vessels; this hypoxia-vasoproliferation is stage II of retinopathy of prematurity. See the image below.

Stage II retinopathy of prematurity. Stage II retinopathy of prematurity.

This process is mediated, in part, by VEGF and is affected by insulinlike growth factor-1 (IGF-1) and other cytokines. These changes in the retina result in retinopathy of prematurity.

Dhaliwal et al found that retinopathy of prematurity occurred with significantly greater frequency and severity in small-for-GA (SGA) infants compared with appropriate-for-GA (AGA) infants.[1] In a review of 1413 infants with birth weight less than 1500 g and/or GA of 26-31 weeks, infants with a birth weight below the tenth percentile for GA were more likely to develop any stage of retinopathy of prematurity than their AGA peers (p< 0.01) and were more likely to develop severe retinopathy of prematurity (GA of 26-27 weeks, p< 0.01; GA of 28-31 weeks, p = 0.01).

Previous
Next

Epidemiology

Frequency

United States

The incidence varies with birth weight but is reported to be approximately 50-70% in infants whose weight is less than 1250 g at birth.

Hussain et al reviewed the incidence and the need for surgery in neonates with retinopathy of prematurity who were born at 22-36 weeks' gestation between July 1989 and June 30, 1997.[2] The incidences were 21.3% (202 of 950 patients) for retinopathy of prematurity of any stage and 4.6% (44 of 950 patients) for retinopathy of prematurity at stage III or worse. No retinopathy of prematurity was noted in infants born after 32 weeks' gestation. No infant born after 28 weeks' gestation needed retinal surgery in this study. Despite the increased survival of ELBW infants, they found a considerable reduction in the incidence and severity of retinopathy of prematurity compared with reports from an earlier period. However, infants born before 28 weeks' gestation and those with birth weights less than 1000 g were at risk to need retinal surgical treatment for retinopathy of prematurity.

Investigators from the Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP) multicenter trial concluded that maintaining oxygen saturation in the high-90% range did not reduce the severity of the retinopathy when compared with the saturations in the low-90% range.[3] However, it did result in more adverse pulmonary events. In a subanalysis of infants who did not have plus disease (ie, tortuosity of vessels) at the time of study entry, the progression to threshold was significantly decreased when compared with the progression in infants with plus disease. Thus, a critical window for oxygen administration may be determined.

International

Retinopathy of prematurity is prevalent worldwide and several reports have detailed the incidence and risk factors associated with the disease.

A Korean study reported a 20.7% incidence (88 of 425 premature babies) and reported that a GA of 28 weeks or less and a birth weight of 1000 g or less were the most significant risk factors.[4] Another study from Singapore reported a 29.2% incidence (165 of 564 ELBW infants).[5] The median age of onset of retinopathy of prematurity was 35 weeks (range, 31-40 wk) postmenstrual age. The risk factors for development of threshold retinopathy of prematurity by regression analysis were maternal preeclampsia, birth weight, pulmonary hemorrhage, duration of ventilation, and duration of continuous positive airway pressure (CPAP).

An observational study from United Kingdom designed to compare the characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development found that the mean birth weights of infants from highly developed countries was 737-763 g compared with 903-1527 g in less-developed countries.[6] Mean GAs of infants from highly developed countries were 25.3-25.6 weeks compared with 26.3-33.5 weeks in less-developed countries. Thus, larger and more mature infants seemed to be developing severe retinopathy of prematurity in less-developed nations. This suggests that individual countries need to develop their own screening programs with criteria suited to their local population.

Mortality/Morbidity

Long-term outcomes for serious disease include severe visual impairment and blindness. In addition, myopia, amblyopia, and strabismus may occur. Repka et al described the need for subsequent ophthalmic intervention in patients with retinopathy of prematurity.[7]

Race

Some reports indicate a decreased incidence of progression to threshold disease in black infants. Most evidence comes from the Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) study.[8] Further evidence that black infants are less likely to develop severe retinopathy of prematurity has been reported in studies of candidemia in ELBW infants.[9] The exact mechanism for the decreased incidence of progression to surgery in black infants has not been described. Bizzaro et al showed a strong genetic predisposition to retinopathy of prematurity when comparing monozygotic twins with dizygotic twins.[10]

Sex

Although some reports indicate a male predilection, the CRYO-ROP study revealed no differences based on sex.[8]

Age

Retinopathy of prematurity is a disease of the immature retina, and the occurrence of retinopathy of prematurity is inversely related to GA. The more premature the infant, the more likely retinopathy of prematurity is to develop.

Previous
Proceed to Clinical Presentation
 
 
Contributor Information and Disclosures
Author

KN Siva Subramanian, MD  Professor of Pediatrics and Obstetrics/Gynecology, Chief of Neonatal Perinatal Medicine, Hospital Ethicist, Georgetown University Hospital

KN Siva Subramanian, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American College of Nutrition, American Society for Parenteral and Enteral Nutrition, American Society of Law, Medicine & Ethics, New York Academy of Sciences, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Coauthor(s)

Monisha Bahri, MBBS, MD  Fellow in Neonatal/Perinatal Medicine, Department of Neonatology, Georgetown University Hospital

Monisha Bahri, MBBS, MD is a member of the following medical societies: American Academy of Pediatrics, Indian Academy of Pediatrics, and Medical Council of India

Disclosure: Nothing to disclose.

Gonzalo (Vike) Vicente, MD, FAAP  Consulting Ophthalmologist, Eye Doctors of Washington

Gonzalo (Vike) Vicente, MD, FAAP is a member of the following medical societies: American Academy of Ophthalmology, American Academy of Pediatrics, American Association for Pediatric Ophthalmology and Strabismus, and American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Oussama Itani, MD, FAAP, FACN  Clinical Associate Professor of Pediatrics and Human Development, Michigan State University; Medical Director, Department of Neonatology, Borgess Medical Center

Oussama Itani, MD, FAAP, FACN is a member of the following medical societies: American Academy of Pediatrics, American College of Nutrition, American College of Physician Executives, and American Heart Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Arun K Pramanik, MD, MBBS  Professor of Pediatrics, Director of Neonatal Fellowship, Louisiana State University Health Sciences Center

Arun K Pramanik, MD, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, National Perinatal Association, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Carol L Wagner, MD  Professor of Pediatrics, Medical University of South Carolina

Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical Women's Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Clinical Nutrition, Massachusetts Medical Society, National Perinatal Association, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD  Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research

Disclosure: Nothing to disclose.

References

  1. [Best Evidence] Dhaliwal CA, Fleck BW, Wright E, Graham C, McIntosh N. Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed. May 2009;94(3):F193-5. [Medline].

  2. Hussain N, Clive J, Bhandari V. Current incidence of retinopathy of prematurity, 1989-1997. Pediatrics. Sep 1999;104(3):e26. [Medline]. [Full Text].

  3. STOP-ROP. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity, a randomized, controlled trial. I: primary outcomes. Pediatrics. Feb 2000;105(2):295-310. [Medline].

  4. Kim TI, Sohn J, Pi SY, Yoon YH. Postnatal risk factors of retinopathy of prematurity. Paediatr Perinat Epidemiol. Mar 2004;18(2):130-4. [Medline].

  5. Shah VA, Yeo CL, Ling YL, Ho LY. Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore. Ann Acad Med Singapore. Mar 2005;34(2):169-78. [Medline].

  6. Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. May 2005;115(5):e518-25. [Medline].

  7. Repka MX, Summers CG, Palmer EA, et al. The incidence of ophthalmologic interventions in children with birth weights less than 1251 grams. Results through 5 1/2 years. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. Sep 1998;105(9):1621-7. [Medline].

  8. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol. Aug 2001;119(8):1110-8. [Medline].

  9. Tadesse M, Dhanireddy R, Mittal M, Higgins RD. Race, Candida sepsis, and retinopathy of prematurity. Biol Neonate. 2002;81(2):86-90. [Medline].

  10. Bizzarro MJ, Hussain N, Jonsson B, et al. Genetic susceptibility to retinopathy of prematurity. Pediatrics. Nov 2006;118(5):1858-63. [Medline].

  11. Hellstrom A, Hard AL, Engstrom E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics. Apr 2009;123(4):e638-45. [Medline].

  12. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. Jul 2005;123(7):991-9. [Medline].

  13. [Guideline] AAP, AAO, and AAPOS. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. Feb 2006;117(2):572-6. [Medline].

  14. Subhani M, Combs A, Weber P, et al. Screening guidelines for retinopathy of prematurity: the need for revision in extremely low birth weight infants. Pediatrics. Apr 2001;107(4):656-9. [Medline].

  15. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. Jun 2008;28(6):831-8. [Medline].

  16. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10(2):133-40. [Medline].

  17. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. Jul 2007;13(7):868-73. [Medline].

  18. Mantagos IS, Vanderveen DK, Smith LE. Emerging treatments for retinopathy of prematurity. Semin Ophthalmol. Mar-Apr 2009;24(2):82-6. [Medline].

  19. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. Feb 17 2011;364(7):603-15. [Medline].

  20. Shalev B, Farr AK, Repka MX. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: seven-year outcome. Am J Ophthalmol. Jul 2001;132(1):76-80. [Medline].

  21. VanderVeen DK, Coats DK, Dobson V, et al. Prevalence and course of strabismus in the first year of life for infants with prethreshold retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity study. Arch Ophthalmol. Jun 2006;124(6):766-73. [Medline].

  22. Good WV, Hardy RJ, Dobson V, et al. The incidence and course of retinopathy of prematurity: findings from the earlytreatment for retinopathy of prematurity study. Pediatrics. Jul 2005;116(1):15-23. [Medline].

  23. Console V, Gagliardi L, De Giorgi A, De Ponti E. Retinopathy of prematurity and antenatal corticosteroids. The Italian ROP Study Group. Acta Biomed Ateneo Parmense. 1997;68 Suppl 1:75-9. [Medline].

  24. Wright KW, Sami D, Thompson L, Ramanathan R, Joseph R, Farzavandi S. A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity. Trans Am Ophthalmol Soc. 2006;104:78-84. [Medline].

  25. Wallace DK. Oxygen saturation levels and retinopathy of prematurity--are we on target?. J AAPOS. Oct 2006;10(5):382-3. [Medline].

  26. [Guideline] AAP, AAPOS, AAO. Screening examination of premature infants for retinopathy of prematurity. A joint statement of the American Academy of Pediatrics, the American Association for Pediatric Ophthalmology and Strabismus, and the American Academy of Ophthalmology. Pediatrics. Aug 1997;100(2 Pt 1):273. [Medline]. [Full Text].

  27. Bremer DL, Palmer EA, Fellows RR, et al. Strabismus in premature infants in the first year of life. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. Mar 1998;116(3):329-33. [Medline].

  28. Brooks SE, Marcus DM, Gillis D, et al. The effect of blood transfusion protocol on retinopathy of prematurity: A prospective, randomized study. Pediatrics. Sep 1999;104(3 Pt 1):514-8. [Medline].

  29. Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. Aug 1984;102(8):1130-4. [Medline].

  30. Connolly BP, McNamara JA, Sharma S, et al. A comparison of laser photocoagulation with trans-scleral cryotherapy in the treatment of threshold retinopathy of prematurity. Ophthalmology. Sep 1998;105(9):1628-31. [Medline].

  31. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Pediatrics. May 1988;81(5):697-706. [Medline].

  32. Dani C, Reali MF, Bertini G, et al. The role of blood transfusions and iron intake on retinopathy of prematurity. Early Hum Dev. Apr 2001;62(1):57-63. [Medline].

  33. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. Dec 2003;121(12):1684-94. [Medline].

  34. Gelman R, Martinez-Perez ME, Vanderveen DK, Moskowitz A, Fulton AB. Diagnosis of plus disease in retinopathy of prematurity using Retinal Image multiScale Analysis. Invest Ophthalmol Vis Sci. Dec 2005;46(12):4734-8. [Medline].

  35. Good WV. The Early Treatment for Retinopathy Of Prematurity Study: structural findings at age 2 years. Br J Ophthalmol. Nov 2006;90(11):1378-82. [Medline].

  36. Higgins RD, Mendelsohn AL, DeFeo MJ, et al. Antenatal dexamethasone and decreased severity of retinopathy of prematurity. Arch Ophthalmol. May 1998;116(5):601-5. [Medline].

  37. Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study. Ophthalmology. Feb 1993;100(2):238-44. [Medline].

  38. Johnson L, Quinn GE, Abbasi S, et al. Severe retinopathy of prematurity in infants with birth weights less than 1250 grams: incidence and outcome of treatment with pharmacologic serum levels of vitamin E in addition to cryotherapy from 1985 to 1991. J Pediatr. Oct 1995;127(4):632-9. [Medline].

  39. Kennedy JE, Todd DA, John E. Progress in Retinopathy of Prematurity. In: Premature Birth and Retinopathy of Prematurity. 1997:73-5.

  40. Lee SK, Normand C, McMillan D, et al. Evidence for changing guidelines for routine screening for retinopathy of prematurity. Arch Pediatr Adolesc Med. Mar 2001;155(3):387-95. [Medline].

  41. McNamara JA, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology. May 1991;98(5):576-80. [Medline].

  42. O'Keefe M, O'Reilly J, Lanigan B. Longer-term visual outcome of eyes with retinopathy of prematurity treated with cryotherapy or diode laser. Br J Ophthalmol. Nov 1998;82(11):1246-8. [Medline]. [Full Text].

  43. Palmer EA, Hardy RJ, Dobson V, et al. 15-year outcomes following threshold retinopathy of prematurity: final resultsfrom the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol. Mar 2005;123(3):311-8. [Medline].

  44. Pearce IA, Pennie FC, Gannon LM, et al. Three year visual outcome for treated stage 3 retinopathy of prematurity: cryotherapy versus laser. Br J Ophthalmol. Nov 1998;82(11):1254-9. [Medline].

  45. Phelps DL. Retinopathy of prematurity. Pediatr Rev. Feb 1995;16(2):50-6. [Medline].

  46. Quinn GE, Dobson V, Kivlin J, et al. Prevalence of myopia between 3 months and 5 1/2 years in preterm infants with and without retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. Jul 1998;105(7):1292-300. [Medline].

  47. Raju TN, Langenberg P, Bhutani V, Quinn GE. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr. Dec 1997;131(6):844-50. [Medline].

  48. Reynolds JD, Hardy RJ, Kennedy KA, et al. Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group [see comments]. N Engl J Med. May 28 1998;338(22):1572-6. [Medline].

  49. Saunders RA, Donahue ML, Christmann LM, et al. Racial variation in retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. May 1997;115(5):604-8. [Medline].

  50. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. May-Jun 2007;38(3):233-7. [Medline].

  51. Vanderveen DK, Mansfield TA, Eichenwald EC. Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. J AAPOS. Oct 2006;10(5):445-8. [Medline].

  52. Wallace DK. Oxygen saturation levels and retinopathy of prematurity--are we on target?. J AAPOS. Oct 2006;10(5):382-3. [Medline].

  53. Young TL, Anthony DC, Pierce E, et al. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS. Jun 1997;1(2):105-10. [Medline].

 
Previous
Next
 
Stage I retinopathy of prematurity.
Scheme of retina of right eye (RE) and left eye (LE) showing zone borders and clock hours used to describe location and extent of retinopathy of prematurity.
Zone I retinopathy of prematurity.
Zone II retinopathy of prematurity.
Zone III retinopathy of prematurity.
Stage II retinopathy of prematurity.
Stage III retinopathy of prematurity.
Retinopathy of prematurity.
Retinopathy of prematurity.
Retinopathy of prematurity.
Retinopathy of prematurity.
Retinopathy of prematurity threshold, according to the Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) cooperative group.
Treatment guidelines, according to the Early Treatment for Retinopathy of Prematurity (ET-ROP) study.
Laser photocoagulation.
Cryotherapy probe application.
Table. Timing of First Eye Examination Based on Gestational Age at Birth
Gestational Age at Birth (wk)Chronologic Age (wk)Postmenstrual Age (wk)
22 *931
23 *831
24731
25631
26531
27431
28432
29433
30434
31 (if necessary)435
32 (if necessary)436
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.